Amarin Corporation plc (ADR) Stock Xetra
Equities
EH3A
US0231112063
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 224M 209M | Sales 2025 * | 231M 216M | Capitalization | 359M 335M |
---|---|---|---|---|---|
Net income 2024 * | -60M -55.99M | Net income 2025 * | -52M -48.52M | EV / Sales 2024 * | 0.63 x |
Net cash position 2024 * | 217M 203M | Net cash position 2025 * | 187M 174M | EV / Sales 2025 * | 0.75 x |
P/E ratio 2024 * |
-5.87
x | P/E ratio 2025 * |
-6.54
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.73% |
Latest transcript on Amarin Corporation plc (ADR)
Managers | Title | Age | Since |
---|---|---|---|
Patrick Holt
CEO | Chief Executive Officer | 52 | 23-07-17 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 22-06-19 |
Compliance Officer | 55 | Nov. 14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 23-02-27 |
Odysseas Kostas
CHM | Chairman | 49 | 23-02-27 |
Keith Horn
BRD | Director/Board Member | 66 | 23-02-27 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- AMRN Stock
- EH3A Stock